Reopened Sharon Regional Medical Center draws patients, rehires staff amid transformation plans
Bryan Burklow, a longtime hospital CEO who is new owner Tenor Health's chief transformation officer, said the hospital reopened with one 12-bed medical-surgical unit, one intensive care unit and all 20 behavioral health beds. More of the beds at the formerly 141-bed hospital will reopen in the future.
'We anticipate that by the beginning of April we'll open up our surgery department and we would anticipate that shortly thereafter we will be able to resume cardiac catheterizations,' Burklow told the Business Times. 'At that point we'd be pretty much full service.'
Sharon Regional Medical Center, caught up in the Steward Health System bankruptcy that began last year, closed Jan. 5 despite efforts to keep it open. Tenor, a California-based hospital management company, has been working since before then to revive Sharon Regional Medical Center and got the Pennsylvania Department of Health's permission on Friday to reopen.
Click here to read more from our partners at the Pittsburgh Business Times.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
Yahoo
18 minutes ago
- Yahoo
Cedars-Sinai's AI tool delivered 24/7 care to 42,000 patients. Now, doctors can focus more on treatment, less on paperwork.
Cedars-Sinai launched CS Connect, an AI-powered platform for 24/7 healthcare support. The platform aims to reduce wait times and administrative tasks, improving care delivery. This article is part of "CXO AI Playbook" — straight talk from business leaders on how they're testing and using AI. Cedars-Sinai is a nonprofit healthcare organization based in Los Angeles. It's comprised of hospitals, clinics, and research facilities. Founded in 1902, Cedars-Sinai has more than 40 locations, employs over 4,500 physicians and nurses, and serves more than 1 million patients every year. Situation analysis Caroline Goldzweig, chief medical officer of Cedars-Sinai Medical Network, told Business Insider that the organization wanted to expand patients' access to primary care in a more efficient and convenient way. For instance, sometimes there are lengthy wait times for in-person doctor's appointments. At the same time, Goldzweig said the organization was looking to reduce the administrative burden on physicians, including patient intake and data entry, so that they could focus on providing care. To address these challenges, the organization launched Cedars-Sinai Connect in 2023. CS Connect is an artificial intelligence-powered virtual platform where patients can access healthcare support 24/7. Goldzweig said the AI technology allows healthcare providers to better support their patients while improving the speed of care delivery. "The other exciting thing is the ability to offer patients care in ways that meet their needs," she said. Key staff and partners Goldzweig told Business Insider that CS Connect was built using K Health, a digital healthcare company providing AI-powered primary and urgent care services. Cedars-Sinai's information technology teams worked with K Health to sync patients' electronic health records into the platform, she said. Cedars-Sinai's enterprise data intelligence and digital strategy teams were also involved in creating CS Connect. They continue to help manage it. AI in action The goal of the AI tool is to enable providers to spend more time counseling patients and making treatment decisions, rather than doing patient intake. To access the AI features, patients log into CS Connect via a mobile app or its website. Goldzweig said a chat feature then starts asking the user questions about their symptoms. The AI algorithm compares the patient's responses to their existing medical records and the records of other patients in the system who had similar symptoms. It then asks more detailed questions about a patient's specific health problems. The chatbot, for example, may prompt the patient to submit photos of their sore throat or rash. Goldzweig said the chat function is similar to how a physician might identify a patient's ailment. The AI then summarizes the patient's information — a task that usually demands manual effort from physicians — and recommends a treatment. The data collected by CS Connect is "part of the efficiency process," Goldzweig said. "It allows the physicians to review it, to understand what's going on, and to validate things with the patient — ask a couple of clarifying questions and maybe get a little bit more history." Physicians can choose to disagree with the AI's recommendations. Goldzweig said either way, they're required to sign off on each patient's treatment plan. Did it work, and how did leaders know? Goldzweig told BI that about 42,000 individual patients have used CS Connect. In April 2025, Cedars-Sinai published a study in the journal Annals of Internal Medicine comparing AI treatment recommendations in CS Connect with final recommendations from doctors. The study reviewed 461 physician-managed visits with AI recommendations for respiratory, urinary, vaginal, eye, and dental symptoms. Results showed that when AI and physician recommendations differed, the AI suggestions were often rated as higher quality. The study found that 77% of AI recommendations were rated as optimal, while 67% of physicians' decisions were rated optimal. For example, patients with recurring urinary tract infections sometimes encounter antibiotic resistance. Goldzweig said the AI was successful at identifying these patients and recommended a bacterial culture before prescribing antibiotics. In contrast, doctors sometimes prescribe medication without testing, which she said could result in the infection coming back. Goldzweig added that the study suggests that the AI tool tends to be more guideline-focused, while physicians have the ability to adapt medical guidelines based on the nuance of a patient's case. Goldzweig said the study has limitations, though. It examined only a few medical conditions and didn't factor in the nuance of individual patient cases. Another limitation is that the medical chart reviewers could see whether the recommendation was made by the AI or a physician. Cedars-Sinai is working to expand CS Connect. The organization is piloting remote patient monitoring technology using AI to help people manage chronic diseases, like high blood pressure. It's also planning to use the AI technology to connect in-person urgent care visits with virtual care. Read the original article on Business Insider
Yahoo
18 minutes ago
- Yahoo
Exelixis Gains Analyst Confidence as Cancer Studies Advances
Exelixis, Inc. (NASDAQ:EXEL) is one of the . The company advances its studies following a significant rise in price targets from analysts. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Based in California, Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on discovering, developing, and commercializing oncology medicines. It is known for its work in oncology, specifically with small-molecule therapies and antibody-drug conjugates. The company's key products include CABOMETYX (cabozantinib) and COMETRIQ. With these products, the company targets difficult-to-treat cancers such as renal cell and medullary thyroid carcinoma. On June 10, 2025, Barclays, while keeping an Equal Weight rating on the stock, raised its price target from $29 to $40. Reflecting the sentiment, UBS also raised its price target on the stock from $38 to $43, while maintaining a Neutral rating. With the new price targets indicating confidence in the company's progress, Exelixis, Inc. (NASDAQ:EXEL) provided updates on its ongoing clinical studies. Study of XL092 has entered Phase 3, where its efficiency with nivolumab is tested in comparison to sunitinib in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who have not received prior systemic anticancer therapy. The company also announced a Phase 1 clinical study on XL309 to estimate its safety and preliminary efficacy, both alone and in combination with olaparib, in treating advanced solid tumors. In addition to these advances in cancer treatment, investors are also intrigued by the company's low volatility, represented by the beta of 0.30 and the potential EPS growth of 32.12% in the next five years. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
